Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 4/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141092 | 0.91 | BCHE (0.44) | HRH3BCHEMCHR1OPRM1OPRD1 | |
| SCHEMBL4147507 | 0.90 | MCHR1 (0.41) | HRH3BCHEMCHR1CYP2D6KCNH2 | |
| SCHEMBL4143084 | 0.89 | KCNH2 (0.47) | HRH3MCHR1CYP2D6KCNH2HTR2C | |
| SCHEMBL4132414 | 0.83 | HRH3 (0.45) | HRH3 | |
| SCHEMBL4136102 | 0.82 | FAAH (0.44) | MCHR1 | |
| SCHEMBL4141778 | 0.81 | HRH3 (0.41) | HRH3BCHEMCHR1OPRM1OPRD1 | |
| SCHEMBL4132197 | 0.80 | HRH3 (0.53) | HRH3MCHR1KCNH2 | |
| SCHEMBL4136371 | 0.80 | HRH3 (0.52) | HRH3BCHEMCHR1 | |
| SCHEMBL4136377 | 0.80 | HRH3 (0.52) | HRH3BCHEMCHR1 | |
| SCHEMBL4135538 | 0.79 | L3MBTL3 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | disclosed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885BCHE 573/4885MCHR1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.